Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DLU2 | ISIN: SE0009414576 | Ticker-Symbol: OND
Frankfurt
06.06.25 | 08:03
0,135 Euro
-0,44 % -0,001
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOPEPTIDES AB Chart 1 Jahr
5-Tage-Chart
ONCOPEPTIDES AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,1340,14206.06.

Aktuelle News zur ONCOPEPTIDES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.05.Oncopeptides AB: Bulletin from the Annual General Meeting in Oncopeptides AB (publ)89Stockholm, Sweden - The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 22 May 2025. At the Annual General Meeting, the following principal resolutions were passed. The...
► Artikel lesen
20.05.Oncopeptides AB: Oncopeptides launches new real-world evidence study of Pepaxti in Spain, first patient enrolled215Stockholm, May 20, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the first patient has been enrolled in its new...
► Artikel lesen
15.05.Oncopeptides Q1 2025 slides: 160% sales growth as European expansion accelerates3
ONCOPEPTIDES Aktie jetzt für 0€ handeln
15.05.Oncopeptides AB: Oncopeptides publishes Q1 report 2025114Stockholm - May 15, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the first quarter 2025. "The first...
► Artikel lesen
16.04.Oncopeptides AB: New Real-World Data support effectiveness and tolerability of Pepaxti in heavily pretreated Multiple Myeloma patients144Stockholm, April 16, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of new real-world data that further...
► Artikel lesen
27.02.Oncopeptides AB: Oncopeptides publishes year-end report 2024339Stockholm - February 27, 2025 - Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2024. "Pepaxti sales increased about 35 percent...
► Artikel lesen
27.01.Italian decision sets up launch of Oncopeptides' Pepaxti8
07.11.24Oncopeptides AB: Oncopeptides publishes Q3 report 2024227Stockholm - November 7, 2024 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2024. "In the...
► Artikel lesen
14.08.24Oncopeptides AB: Oncopeptides publishes Q2 report 2024386Stockholm - August 14, 2024 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2024. "During...
► Artikel lesen
9 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5